STAT+: Inside Moderna and Merck’s cancer vaccine triumph

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and pandemic-era complications.

It is the first time that an mRNA-based cancer vaccine has succeeded in a large-scale study.

Cancer vaccines could transform treatment and prevention – but misinformation about mRNA vaccines threatens their potential  CNN

Hype for Moderna’s Cancer Vaccine Is Running Ahead of the Math  WSJ

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available and why researchers hope the approach can be used against other cancers.

Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK

US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough." Researchers have for years been trying to apply mRNA treatments against cancer, but this was the first time such a d

A personalised mRNA cancer vaccine has produced positive results in a final-stage trial involving skin cancer, raising hopes that this approach could work against many cancers

Skin cancer breakthrough delivers second act for Moderna's mRNA vaccines  thenationalnews.com

Technology behind blockbuster Covid-19 jabs is now yielding promising results in oncology treatment

Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor

The treatment involves pairing Merck's immunotherapy drug with a customized mRNA vaccine that instructs the immune system to attack specific cancer cells.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."

Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%.

The vaccine is built on the mRNA platform that allowed Moderna to quickly roll out COVID-19 vaccines five years ago.

Moderna, Merck breakthrough could usher in wave of cancer vaccines  Reuters

Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

Moderna, Merck mRNA Cancer Vaccine Cuts Recurrence And Spread Of Melanoma  HuffPost

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health

US stocks are ticking higher after the US Treasury Department said it will buy more US government bonds in a move that eased pressure on financial markets worldwide.

US stocks are ticking higher after the US Treasury Department said it will buy more US government bonds in a move that eased pressure on financial markets worldwide.

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Bespoke cancer vaccines show promise. But will the NHS pay?  The Times

The vaccine reportedly thwarted the cancer's return and spread.

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Moderna-Merck melanoma therapy averts cancer recurrence in study  Chicago Tribune

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed